The company did not disclose which subvariant of Omicron the vaccine would be targetting
PHOTO
Pfizer Inc and its German partner BioNTech SE said on Wednesday they had started a mid-stage study of a modified bivalent COVID-19 vaccine which also targets an Omicron variant.
The company did not disclose which subvariant of Omicron the vaccine would be targetting. (Reporting by Leroy Leo in Bengaluru; Editing by Vinay Dwivedi)
Reuters
Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.
